TOKYO (Reuters) -- Japan's Hitachi Ltd said on Wednesday it would sell its listed chemicals unit and diagnostic imaging business in a deal totaling 673 billion yen ($6.2 billion), as the Japanese industrial conglomerate overhauls its business portfolio.
Showa Denko said it was offering to pay a total of 964 billion yen for shares in Hitachi Chemical, including from Hitachi as well as the market.
Showa Denko beat rival bids from Nitto Denko Corp, U.S. buyout funds Bain Capital LP and Carlyle Group LP.
Hitachi's diagnostic imaging business will be sold to Fujifilm Holdings Corp for 179 billion yen as the Japanese photocopier and camera manufacturer deepens its push into health care.
The deal follows a recent series of acquisitions by Fujifilm, including a drugmaking business from U.S.-based Biogen Inc and two biotechnology units from JXTG Holdings Inc as growth at its legacy photocopy business stagnates.
Hitachi has been among the most aggressive of Japan's conglomerates in reorganizing its business, selling noncore assets while buying foreign businesses to expand digital businesses.
The Japanese government has also pointed out potential conflicts of interest between publicly traded parent companies and their listed subsidiaries and set corporate governance guidelines for those companies.
Hitachi expects the sale to generate 389 billion yen in special profits.